Finalists of the European Biotechnica Award nominated


Hanover - The jury of the European Biotechnica Award has selected the three finalists for 2009: The nominees are the biopharmaceutical companies NovImmune, Switzerland, TRION Pharma GmbH, Germany, and Vivalis, France. The award recognizes the achievements of young, innovative European companies from the areas of biotechnology and the life sciences.
NovImmune develops monoclonal antibodies for the treatment of inflammatory and immune-related disorders. The company is based in Plan-les-Quates, near Geneva, Switzerland, and so far has generated seven monoclonal antibodies with the intent to treat immune-related disorders.
TRION Pharma is a biopharmaceutical company that develops trifunctional antibodies called Triomab® at its site in Munich. They are based on a platform technology for which TRION Pharma holds IP rights around the world. Triomab® antibodies simultaneously activate multiple immune defence mechanisms against cancer.
Vivalis provides the pharmaceutical industry with cell-based solutions for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. Headquartered in France, the company specialises in the field of embryonic stem cells and their practical applications in human and veterinary medicine.
The international jury of experts, consisting of eleven members and chaired by Prof. Dr. Peter Stadler, CEO of Artemis Pharmaceuticals in Cologne, will decide on the ultimate winner immediately before the award ceremony during the BIOTECHNICA opening event on 5 October. The winner will receive prize money of EUR 30,000. In addition, all finalists will receive numerous non-cash prizes. The award will be presented by opening speakers Janez Potocnik, EU Commissioner for Science and Research, Dr. Philipp Rösler; Minister of Economics, Lower Saxony; Dr. Stefan Marcinowski, Member of the Board of Executive Directors of BASF and President of the German Association of Biotechnology Industries; and Kary Mullis, winner of the Nobel Prize in Chemistry.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%


  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%


  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%


  • WILEX4.20 EUR418.5%
  • FORMYCON27.70 EUR316.5%
  • 4SC4.65 EUR315.2%


  • MOLOGEN4.92 EUR-53.7%
  • BIOFRONTERA2.30 EUR-28.6%
  • PAION2.51 EUR-22.8%

No liability assumed, Date: 25.05.2015

Current issue

All issues